- Home
- TGB vs CDNA Comparison
TGB vs CDNA Comparison
Compare TGB & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TGB | CDNA |
|---|---|---|
| Founded | 1966 | 1998 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Medical Specialities |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2B | 3.3B |
| IPO Year | 2002 | 2007 |
Fundamental Metrics
Financial Performance| Metric | TGB | CDNA |
|---|---|---|
| Price | $7.51 | $68.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 7 |
| Target Price | $10.27 | ★ $61.67 |
| AVG Volume (30 Days) | ★ 3.5M | 1.4M |
| Earning Date | 11-11-2026 | 10-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.13 |
| Revenue | N/A | ★ $48,324,000.00 |
| Revenue This Year | $86.51 | $30.36 |
| Revenue Next Year | $27.19 | $6.23 |
| P/E Ratio | ★ N/A | $32.28 |
| Revenue Growth | N/A | ★ 18.93 |
| 52 Week Low | $3.93 | $14.23 |
| 52 Week High | $9.82 | $72.71 |
Technical Indicators
Market Signals| Indicator | TGB | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 36.96 | 62.36 |
| Support Level | $7.44 | $17.30 |
| Resistance Level | $8.14 | $72.51 |
| Average True Range (ATR) | 0.36 | 4.44 |
| MACD | -0.12 | -0.09 |
| Stochastic Oscillator | 13.84 | 67.27 |
Price Performance
Historical ComparisonAbout TGB Taseko Mines Ltd.
Trekor Metals Ltd is a North American copper producer with a development pipeline of minerals projects and properties in Canada and the United States. The company's properties include Gibraltar Mine, Florence Copper, Yellowhead Project, Aley Project, and New Prosperity.
About CDNA CareDx Inc.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.